Drugs / LY3321367
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03099109 | Apr 2017 → Dec 2019 | neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02791334 | Jun 2016 → May 2020 | cutaneous melanoma, hormone receptor-positive breast cancer, malignant pancreatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3321367 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03099109 ↗ |
| Action | Inhibit | “Blocking TIM-3” PMID 33514524 ↗ Jan 2021 |
| Modality | Monoclonal antibody | “a novel, first-in-class, TIM-3 mAb” PMID 33514524 ↗ Jan 2021 |
| Route | Intravenous | “LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle” NCT02791334 ↗ |